ArticleJournal of translational medicine2026
Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aimed to investigate whether effective management of multiple lifestyle risk factors could mitigate the elevated risk of metabolic dysfunction-associated steatotic liver disease (MASLD) among individuals with chronic kidney disease (CKD).
methodsWe analyzed data from the UK Biobank, including 9,877 patients with CKD and 421,043 non-CKD controls, with follow-up through October 31, 2022. Eight lifestyle-related MASLD risk factors (body mass index, diet, physical activity, alcohol consumption, smoking, social connection, sedentary behavior, and sleep duration) were assessed and jointly summarized to reflect the degree of lifestyle risk factor management. Cox proportional hazards models were used to evaluate associations between cumulative lifestyle risk factor management and incident MASLD. Effect modification by sex, type 2 diabetes (T2D), hyperlipidemia, and hypertension was examined using multiplicative interaction terms. All models were adjusted for a comprehensive set of covariates. Missing data were handled using multiple imputation with chained equations, and several sensitivity analyses were conducted to test the robustness.
resultsAmong individuals with CKD, progressively better joint management of lifestyle risk factors was associated with a stepwise reduction in incident MASLD risk. Each additional lifestyle risk factor managed was associated with a 14% lower risk of MASLD. Optimal lifestyle risk factor control (≥ 7 factors managed) was associated with a 64% reduction in MASLD (HR: 0.36; 95% CI: 0.16–0.79). Notably, among CKD patients achieving optimal lifestyle control MASLD risk was attenuated to a level comparable to that of non-CKD controls (HR: 0.95; 95% CI: 0.49–1.84). The protective association of combined lifestyle risk factor management was less pronounced in individuals with hyperlipidemia or T2D compared to those without these conditions (P for interaction < 0.001).
conclusionsIn individuals with CKD, cumulative adherence to optimal lifestyle risk factor management exhibited an inverse association with MASLD development. These findings suggest that comprehensive control of modifiable lifestyle risks may be associated with a mitigation of the elevated MASLD susceptibility observed in CKD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.